OTCPK:PCYN

Stock Analysis Report

Executive Summary

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and other skin problems primarily in the United States.

Snowflake

Fundamentals

Good value with mediocre balance sheet.

Risks

  • Procyon is not covered by any analysts.

Share Price & News

How has Procyon's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:PCYN

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

-13.3%

OTCPK:PCYN

9.9%

US Medical Equipment

1.6%

US Market

PCYN underperformed the Medical Equipment industry which returned 9.7% over the past year.

PCYN underperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

PCYNIndustryMarket
7 Day0%0.5%-0.02%
30 Day0%0.09%2.7%
90 Dayn/a2.0%1.4%
1 Year-13.3%-13.3%10.8%9.9%3.8%1.6%
3 Year18.2%18.2%69.0%63.9%45.2%35.8%
5 Year136.4%136.4%136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Procyon's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Procyon undervalued based on future cash flows and its price relative to the stock market?

23%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Procyon's share price is below the future cash flow value, and at a moderate discount (> 20%).

Procyon's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Procyon is good value based on earnings compared to the US Medical Equipment industry average.

Procyon is good value based on earnings compared to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Procyon, we can't assess if its growth is good value.


Price Based on Value of Assets

Procyon is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Procyon expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.1%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Procyon has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

  • Examine whether Procyon is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Procyon's filings and announcements here.
  • Explore growth companies in the Healthcare industry.

Past Performance

How has Procyon performed over the past 5 years?

-4.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Procyon's year on year earnings growth rate was negative over the past 5 years, however the most recent earnings are above average.

Procyon has become profitable in the last year making the earnings growth rate difficult to compare to the 5-year average.

Procyon has become profitable in the last year making it difficult to compare the US Medical Equipment industry average.


Return on Equity

Procyon has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Procyon used its assets less efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Procyon has become profitable over the past 3 years. This is considered to be a significant improvement in its use of capital (Return on Capital Employed).


Next Steps

Financial Health

How is Procyon's financial position?


Financial Position Analysis

Procyon is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Procyon has no long term commitments.


Debt to Equity History and Analysis

Unable to establish if Procyon's level of debt is high without past debt data.

Unable to establish if Procyon's debt level has increased without past 5-year debt data.

Operating cash flow is negative therefore debt is not well covered.

Procyon has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

High level of physical assets or inventory.

Debt is not covered by short term assets, assets are -7398.9x debt.


Next Steps

Dividend

What is Procyon's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Procyon's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Procyon's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Procyon has not reported any payouts.

Unable to verify if Procyon's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Procyon has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

What is the CEO of Procyon's salary, the management and board of directors tenure and is there insider trading?

7.3yrs

Average management tenure


CEO

Justice Anderson (42yo)

1.7yrs

Tenure

US$230,024

Compensation

Mr. Justice W. Anderson has been Chief Executive Officer and President of Procyon Corporation since January 9, 2018. Mr. Anderson served as a Vice President of Sales & Marketing at Procyon Corporation sinc ...


CEO Compensation Analysis

Justice's remuneration is lower than average for companies of similar size in United States of America.

Justice's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

7.3yrs

Average Tenure

49yo

Average Age

The average tenure for the Procyon management team is over 5 years, this suggests they are a seasoned and experienced team.


Board Age and Tenure

12.8yrs

Average Tenure

72yo

Average Age

The average tenure for the Procyon board of directors is over 10 years, this suggests they are a seasoned and experienced board.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • James Anderson (49yo)

    CFO & Director

    • Tenure: 12.8yrs
    • Compensation: US$168.88k
  • Justice Anderson (42yo)

    CEO, President & Director

    • Tenure: 1.7yrs
    • Compensation: US$230.02k
  • George Borak (58yo)

    Vice President of Sales - Amerx Health Care Corp.

    • Tenure: 7.3yrs
    • Compensation: US$175.85k

Board Members

  • James Anderson (49yo)

    CFO & Director

    • Tenure: 12.8yrs
    • Compensation: US$168.88k
  • Fred Suggs (72yo)

    Independent Director

    • Tenure: 24.7yrs
  • Justice Anderson (42yo)

    CEO, President & Director

    • Tenure: 1.7yrs
    • Compensation: US$230.02k
  • Regina Anderson (72yo)

    Chairman

    • Tenure: 14yrs
    • Compensation: US$133.86k
  • Michael Foley (81yo)

    Independent Director

    • Tenure: 13.7yrs
  • Joseph Treshler (66yo)

    Independent Director

    • Tenure: 6.7yrs
  • Paul Kudelko (79yo)

    Independent Director

    • Tenure: 5.8yrs

Company Information

Procyon Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Procyon Corporation
  • Ticker: PCYN
  • Exchange: OTCPK
  • Founded: 1987
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$2.100m
  • Shares outstanding: 8.08m
  • Website: https://www.procyoncorp.com

Number of Employees


Location

  • Procyon Corporation
  • 1300 South Highland Avenue
  • Clearwater
  • Florida
  • 33756
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PCYNOTCPK (Pink Sheets LLC)YesCommon StockUSUSDDec 1996

Biography

Procyon Corporation, together with its subsidiaries, develops and markets proprietary medical products for use in the treatment of pressure ulcers, stasis ulcers, wounds, dermatitis, inflammation, and othe ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/18 23:39
End of Day Share Price2019/08/19 00:00
Earnings2019/03/31
Annual Earnings2018/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.